Navigation Links
Peptimmune Presentations at Upcoming Events
Date:10/28/2008

immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peptimmune Announces First Close of Series D Private Financing
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
4. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
(Date:2/26/2015)... February 26, 2015 The Movement for ... to support life extension technologies and awareness. The event ... Coordinated Time, on March 21st 2015, in a live ... , Eric Schulke, Founder of MILE, says, “Our lives ... urgency. The Movement for Indefinite Life Extension is raising ...
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... -- The Healthcare and Science business of Thomson ... of Web of Science (R) have remained strong, ... to their portfolio of products. Web of Science ... administrators, faculty and students access to more than 11,000 ...
... , Experienced Executive to Lead Personalized Medicine Company in Next Phase ... AssureRx , a personalized medicine company, ... as its new President and CEO. , , Burns ... in the strategic management of science and technology for pharmaceutical, diagnostic, ...
... SAN MARINO, Calif., June 9 Epeius Biotechnologies, Rexin-G is ... if you will, a tiny particle that can travel freely ... tumors that have spread far and wide. Imagine an ... to high concentrations within the flagrant, otherwise intractable tumors with ...
Cached Biology Technology:Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate 2AssureRx Adds New CEO 2The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers 2
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... 2015  Analyst Report Issued by Small Cap IR. In 2011, ... planet-wide, transactions at merchants on the leading payment cards rose ... credit, debit, and prepaid cards reached 6.54 billion.  Eight million ... card usage in 2012, and credit and debit card fraud ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... of insect species. How great is it, exactly? We do ... Museum of Natural History published a study on tropical ... this question. The paper was published in the open access, ... Caterino and Alexey Tishechkin have named 138 new species within ...
... This press release is available in German ... Chemie " might help to work out strategies for developing ... and Eckhard Mandelkow report, methylene blue inactivates molecular residues that ... a multi-talented substance with a long history. The synthetic compound ...
... study by researchers from Los Alamos National Laboratory and a ... development for the treatment of hepatitis C virus (HCV), targets ... ever seen with anti-HCV drugs within 12 hours of ... 150 million people worldwide. It is the leading cause of ...
Cached Biology News:Little did we know about beetle diversity: Astonishing 138 new species in a single genus 2Researchers decipher modus operandi of potential Alzheimer's drug 2Researchers decipher modus operandi of potential Alzheimer's drug 3Computer modeling reveals how surprisingly potent hepatitis C drug works 2
... WinList come straight from the folks who ... automatic region positioning, N-Stat regions, and presentation-quality ... thoughtful conversations, and careful design. Of course, ... are still there, too. WinList leads the ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Biology Products: